InMode (NASDAQ:INMD) Share Price Passes Above 200 Day Moving Average – Should You Sell?

InMode Ltd. (NASDAQ:INMD) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $14.17 and traded as high as $15.36. InMode shares last traded at $15.28, with a volume of 516,721 shares.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on INMD shares. Robert W. Baird dropped their target price on InMode from $17.00 to $14.00 and set a “neutral” rating on the stock in a report on Thursday, May 7th. Barclays set a $19.00 price objective on shares of InMode and gave the company an “overweight” rating in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $16.00.

InMode Price Performance

The stock has a market capitalization of $878.29 million, a P/E ratio of 11.24 and a beta of 1.91. The stock’s fifty day moving average is $14.05 and its 200-day moving average is $14.17.

InMode (NASDAQ:INMD) last announced its quarterly earnings results on Wednesday, May 6th. The healthcare company reported $0.25 earnings per share for the quarter, missing analysts’ consensus estimates of $0.30 by ($0.05). InMode had a return on equity of 13.47% and a net margin of 23.27%.The company had revenue of $82.02 million during the quarter, compared to analyst estimates of $79.84 million. During the same period in the prior year, the firm earned $0.31 EPS. InMode’s quarterly revenue was up 5.3% on a year-over-year basis.

Institutional Investors Weigh In On InMode

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Royal Bank of Canada raised its position in shares of InMode by 5.7% in the first quarter. Royal Bank of Canada now owns 242,398 shares of the healthcare company’s stock valued at $4,299,000 after purchasing an additional 13,032 shares during the period. AQR Capital Management LLC bought a new stake in shares of InMode during the 1st quarter worth $317,000. Goldman Sachs Group Inc. boosted its holdings in shares of InMode by 234.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,123,756 shares of the healthcare company’s stock worth $19,935,000 after buying an additional 788,157 shares during the period. American Century Companies Inc. grew its stake in InMode by 132.9% in the 2nd quarter. American Century Companies Inc. now owns 44,240 shares of the healthcare company’s stock valued at $639,000 after buying an additional 25,246 shares during the last quarter. Finally, Marshall Wace LLP grew its stake in InMode by 270.7% in the 2nd quarter. Marshall Wace LLP now owns 555,573 shares of the healthcare company’s stock valued at $8,022,000 after buying an additional 405,707 shares during the last quarter. 68.04% of the stock is currently owned by institutional investors and hedge funds.

InMode Company Profile

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.